GLSI · Greenwich LifeSciences, Inc.
$15.97
+0.66 (+4.28%)
At close · Aug 21
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 11, 2026
Market Cap
$254.52M
Shares
14.68M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$19.36M
-11.2%
FY2025
Diluted EPS
-$1.43
-6.7%
FY2025
Operating Cash Flow
-$9.91M
-36.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $20.3M | $17.22M | $15.48M | $7.7M | $6.48M | $3.56M | $1.06M | $2.61M | |
| $2.36M | $2.23M | $2.16M | $1.63M | $1.56M | $1.04M | $806.19K | $818.89K | |
| $22.66M | $19.45M | $17.64M | $9.33M | $8.04M | $4.6M | $1.86M | $3.43M | |
| -$22.66M | -$19.45M | -$17.64M | -$9.33M | -$8.04M | -$4.6M | -$1.86M | -$3.43M | |
| $186.64K | $89.7K | $223.01K | $436.06K | $215.02K | $27.37K | $832 | — | |
| -$22.47M | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -$4.57M | -$1.86M | -$3.43M | |
| USD/shares | — | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | — | — |
| USD/shares | — | -$1.43 | -$1.34 | -$0.69 | -$0.61 | — | — | — |
| shares | — | 13.53M | 13.01M | 12.85M | — | 12.94M | 9.5M | 2.26M |
| shares | — | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M | 9.5M | 2.26M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.22×
EV/EBIT
—
Peer median 10.01×
P/E (TTM)
—
Peer median 11.22×
Peer medians compare against the 314 similar-size Biotechnology companies (of 546 listed).
Key facts
CIK
1799788
CUSIP
396879108
13F (30d)
55 filings
55 filers
Visit website
Investor relations